Form N-VP/A AuguStar Variable Accoun
Tweet
Share
E-mailTop Explorer · Top Plus · Top Tradition ·
Investar Vision/Top Spectrum · Top 1
AuguStarSM Life Insurance Company
AuguStarSM Variable Account A and B
Supplement dated November 25, 2024
to the Prospectuses dated May 1, 2019 and
Update Notices dated April 30, 2024
The following supplements the prospectuses dated May 1, 2019, and the update notices dated April 30, 2024, as previously supplemented. Please read this supplement in conjunction with your Prospectus and update notice and retain it for future reference.
Appendix A – Funds Available Under the Contract
On or about November 25, 2024, the portfolios listed below removed their subadvisers, updated their fees, and changed their names. Appendix A is revised, effective upon such changes:
| Type/ Investment Objective |
Fund and Adviser/Subadviser
|
Current Expenses
|
Average Annual Total Returns (as of 12/31/23) | ||
| 1 year | 5 year | 10 year | |||
|
Allocation
|
AVIP Constellation Dynamic Risk Balanced Portfolio
Adviser: Constellation Investments, Inc. |
0.88% | 12.90% | 8.97% | N/A |
| Allocation |
AVIP Constellation Managed Risk Balanced Portfolio
Adviser: Constellation Investments, Inc. |
0.65% | 13.89% | N/A | N/A |
| Allocation |
AVIP Constellation Managed Risk Moderate Growth Portfolio
Adviser: Constellation Investments, Inc. |
0.65% | 16.15% | N/A | N/A |
| Allocation |
AVIP Constellation Managed Risk Growth Portfolio Adviser: Constellation Investments, Inc. |
0.66% | 19.62% | N/A | N/A |
Any changes made in Appendix A above are incorporated throughout your documents.
1
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Village Voyage: Where northern China’s countryside finds new rhythms
- Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer
- When Crypto Falls: Reading Cycle Turns to Build a Broader Long Position
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
